DE69841663D1 - Verwendung von methylnaltrexon und verwandten verbindungen - Google Patents

Verwendung von methylnaltrexon und verwandten verbindungen

Info

Publication number
DE69841663D1
DE69841663D1 DE69841663T DE69841663T DE69841663D1 DE 69841663 D1 DE69841663 D1 DE 69841663D1 DE 69841663 T DE69841663 T DE 69841663T DE 69841663 T DE69841663 T DE 69841663T DE 69841663 D1 DE69841663 D1 DE 69841663D1
Authority
DE
Germany
Prior art keywords
opioid
administration
induced
side effects
methylnaltrexone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69841663T
Other languages
English (en)
Inventor
William Drell
Joseph F Foss
Michael F Roizen
Jonathan Moss
Chun-Su Yuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arch Development Corp
UR Labs Inc
Original Assignee
Arch Development Corp
UR Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/120,703 external-priority patent/US6274591B1/en
Application filed by Arch Development Corp, UR Labs Inc filed Critical Arch Development Corp
Application granted granted Critical
Publication of DE69841663D1 publication Critical patent/DE69841663D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69841663T 1997-11-03 1998-11-03 Verwendung von methylnaltrexon und verwandten verbindungen Expired - Lifetime DE69841663D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/962,742 US5972954A (en) 1997-11-03 1997-11-03 Use of methylnaltrexone and related compounds
US09/120,703 US6274591B1 (en) 1997-11-03 1998-07-22 Use of methylnaltrexone and related compounds
PCT/US1998/023485 WO1999022737A1 (en) 1997-11-03 1998-11-03 Use of methylnaltrexone and related compounds

Publications (1)

Publication Number Publication Date
DE69841663D1 true DE69841663D1 (de) 2010-06-24

Family

ID=25506291

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69841663T Expired - Lifetime DE69841663D1 (de) 1997-11-03 1998-11-03 Verwendung von methylnaltrexon und verwandten verbindungen

Country Status (3)

Country Link
US (1) US5972954A (de)
AT (1) ATE467415T1 (de)
DE (1) DE69841663D1 (de)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030211157A1 (en) * 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US20040024006A1 (en) * 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US6274591B1 (en) * 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) * 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
DK1685839T3 (da) 1997-12-22 2013-06-24 Euro Celtique Sa Farmaceutisk oral doseringsform omfattende en kombination af en opioidagonist og opioidantagonist
US6451806B2 (en) 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU776666B2 (en) 2000-02-08 2004-09-16 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
EP1404323B1 (de) * 2001-06-05 2009-10-28 The University of Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
US7968119B2 (en) * 2001-06-26 2011-06-28 Farrell John J Tamper-proof narcotic delivery system
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
WO2003013525A1 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
EP2236161A1 (de) 2001-10-18 2010-10-06 Nektar Therapeutics Polymerkonjugate von Opioid-Antagonisten
WO2004014291A2 (en) * 2002-02-04 2004-02-19 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
US20050011468A1 (en) * 2002-02-04 2005-01-20 Jonathan Moss Use of methylnaltrexone in treating gastrointestinal dysfunction in equines
CA2478515C (en) 2002-04-05 2010-09-28 Purdue Pharma Pharmaceutical preparation containing oxycodone and naloxone
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US7381721B2 (en) * 2003-03-17 2008-06-03 Adolor Corporation Substituted piperidine compounds
JP2006522817A (ja) * 2003-04-08 2006-10-05 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 過敏性腸症候群を処置するための末梢オピオイドアンタゴニスト、特にメチルナルトレキソンの使用
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
AU2004229464A1 (en) * 2003-04-08 2004-10-28 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
AU2013203378B2 (en) * 2003-04-08 2016-09-15 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
AR047936A1 (es) 2003-04-30 2006-03-15 Purdue Pharma Ltd Forma de dosificacion transdermica resistente a la manipulacion
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
US6992090B2 (en) * 2003-06-16 2006-01-31 Adolor Corporation Substituted piperidine compounds and methods of their use
US8946262B2 (en) * 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
US20060182692A1 (en) * 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
HRP20140361T1 (hr) * 2003-12-16 2014-05-23 Nektar Therapeutics Monodisperzne smjese pegiliranog naloksola
US7087749B2 (en) * 2004-03-11 2006-08-08 Adolor Corporation Substituted piperidine compounds and methods of their use
EP1604666A1 (de) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
US20060063792A1 (en) * 2004-09-17 2006-03-23 Adolor Corporation Substituted morphinans and methods of their use
CN101137378A (zh) * 2005-01-20 2008-03-05 普罗热尼奇制药公司 甲基纳曲酮和相关化合物治疗术后胃肠功能障碍的用途
EP1702558A1 (de) 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
CN101171010B (zh) 2005-03-07 2014-09-17 芝加哥大学 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
US7538110B2 (en) 2005-10-27 2009-05-26 Adolor Corporation Opioid antagonists
US20070185145A1 (en) * 2006-02-03 2007-08-09 Royds Robert B Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same
KR101486228B1 (ko) 2006-06-19 2015-01-26 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
TW200815451A (en) * 2006-08-04 2008-04-01 Wyeth Corp 6-carboxy-normorphinan derivatives, synthesis and uses thereof
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
CA2682129A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
PT2139890E (pt) 2007-03-29 2014-09-03 Wyeth Llc Antagonistas do receptor opióide periférico e respectivas utilizações
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
US8883817B2 (en) * 2007-10-18 2014-11-11 Aiko Biotechnology Combination analgesic employing opioid and neutral antagonist
US8748448B2 (en) 2007-10-18 2014-06-10 Aiko Biotechnology Combination analgesic employing opioid agonist and neutral antagonist
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2240489A1 (de) 2008-02-06 2010-10-20 Progenics Pharmaceuticals, Inc. HERSTELLUNG UND VERWENDUNG VON (R), (R)-2,2ýBIS-METHYLNALTREXON
EP2278966B1 (de) 2008-03-21 2019-10-09 The University of Chicago Behandlung mit opioid-antagonisten und mtor-inhibitoren
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010103039A1 (en) 2009-03-10 2010-09-16 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US20100311782A1 (en) 2009-06-08 2010-12-09 Adolor Corporation Substituted piperidinylpropanoic acid compounds and methods of their use
EA029096B1 (ru) 2010-03-11 2018-02-28 Вайет Ллк Твердая лекарственная форма для перорального введения, содержащая метилналтрексон
US20140066475A1 (en) 2012-09-04 2014-03-06 Euro-Celtique S.A. Method For Treating Pruritus
KR20180037074A (ko) 2013-07-23 2018-04-10 유로-셀티큐 에스.에이. 장내 세균총이상을 초래하고/하거나 장내 박테리아 전위에 대한 위험을 증가시키는 질환과 통증으로 인해 고통받고 있는 환자에서 통증을 치료하는데 사용하기 위한 옥시코돈과 날록손의 조합물
CN113747882A (zh) 2019-05-07 2021-12-03 博士医疗爱尔兰有限公司 甲基纳曲酮的液体口服剂量制剂

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility

Also Published As

Publication number Publication date
US5972954A (en) 1999-10-26
ATE467415T1 (de) 2010-05-15

Similar Documents

Publication Publication Date Title
ATE467415T1 (de) Verwendung von methylnaltrexon und verwandten verbindungen
CA2312234A1 (en) Use of methylnaltrexone and related compounds
HK1055078A1 (zh) 使用纳布啡和鸦片拮抗剂治疗疼痛的方法
CY1109264T1 (el) Νεες μεθοδοι για την θεραπεια και αποτροπη ειλεου
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
RU2005113996A (ru) Способы лечения боли введением антагониста фактора роста нервов и опиоидного анальгетика, и содержащие их композиции
DE60234183D1 (de) Verwendung von methylnaltrexon zur behandlung von immunsuppression
JPS61260025A (ja) オピオイド誘発の耐性および依存症における禁断症候群の抑制
AR039336A1 (es) Sistemas analgesicos transdermicos con potencial de abuso reducido
RU2009125597A (ru) Пролекарства и способы их получения и применения
TR200400653T4 (tr) Farmasötik kompozisyonlar.
WO2002013801A3 (en) Method of treating the syndrome of coronary heart disease risk factors in humans
RU2007149044A (ru) Твердые лекарственные формы наркотических лекарственных средств с улучшенным всасыванием при трансбуккальном введении
MXPA03007885A (es) Norbuprenorfina n-but-3-enilo y metodos de uso.
NO894295L (no) Fremgangsmaate for behandling av interstitiell cystitt.
ATE375149T1 (de) Behandlung von entzug
ATE268174T1 (de) Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen
ATE465735T1 (de) Verwendung einer kombination von morphin und mindestens einem opiatantagonisten zur behandlung von opiatabhängigkeit und zur verhinderung des nicht-oralen opiatmissbrauchs bei opiatsüchtigen
Hanks The clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain
LV12656A (lv) Medicinal formulation and a method for treating opium drug addiction
GR3018335T3 (en) Use of a pure narcotic antagonist, e.g. nalmefene, naltrexone, naloxone or diprenorphine, in the treatment of mast cell disease.
Rozen et al. Coadministration of an opioid agonist and antagonist for pain control
Blaine Early clinical studies of levo-alpha acetylmethadol (LAAM): an opiate for use in the medical treatment of chronic heroin dependence
RU99127690A (ru) Способ лечения опийной наркомании

Legal Events

Date Code Title Description
8364 No opposition during term of opposition